Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

Rajiv Agarwal, Stefan D Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack, Amer Joseph, FIDELIO-DKD and FIGARO-DKD Investigators, Rajiv Agarwal, Stefan D Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack, Amer Joseph, FIDELIO-DKD and FIGARO-DKD Investigators

Abstract

Despite the standard of care, patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) progress to dialysis, are hospitalized for heart failure and die prematurely. Overactivation of the mineralocorticoid receptor (MR) causes inflammation and fibrosis that damages the kidney and heart. Finerenone, a nonsteroidal, selective MR antagonist, confers kidney and heart protection in both animal models and Phase II clinical studies; the effects on serum potassium and kidney function are minimal. Comprising the largest CKD outcomes program to date, FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) and FIGARO-DKD (FInerenone in reducinG cArdiovascular moRtality and mOrbidity in Diabetic Kidney Disease) are Phase III trials investigating the efficacy and safety of finerenone on kidney failure and cardiovascular outcomes from early to advanced CKD in T2D. By including echocardiograms and biomarkers, they extend our understanding of pathophysiology; by including quality of life measurements, they provide patient-centered outcomes; and by including understudied yet high-risk cardiorenal subpopulations, they have the potential to widen the scope of therapy in T2D with CKD. Trial registration number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049).

Keywords: CKD; albuminuria; clinical trial; diabetic kidney disease; mineralocorticoid receptor antagonist.

© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.

Figures

FIGURE 1
FIGURE 1
Schematic representation of the pathophysiological effects of MR overactivation and the subsequent impact of MRA intervention using finerenone or spironolactone. K+, potassium; Na+, sodium
FIGURE 2
FIGURE 2
Percentage of patients with a treatment-emergent adverse event of hyperkalemia defined as serum potassium ≥5.6 mEq/L in Phase II finerenone trials. Data are point estimates ± 95% CIs. eple: eplerenone; F: finerenone; HFrEF: heart failure with reserved ejection fraction; spiro: spironolactone.
FIGURE 3
FIGURE 3
FIDELIO-DKD and FIGARO-DKD endpoints. aKidney failure defined as occurrence of ESKD (initiation of chronic dialysis for ≥90 days or renal transplantation) or sustained eGFR <15 mL/min/1.73 m2. HF: heart failure; HRQoL: health-related quality of life; MI: myocardial infarction.
FIGURE 4
FIGURE 4
(A) Overlap of patient populations according to inclusion values for UACR and eGFR in the FIDELIO-DKD and the FIGARO-DKD trials. (B) Pooled data showing the baseline KDIGO risk categories of patients included in the FIDELIO-DKD and FIGARO-DKD trials (KDIGO score risk category data were missing for 4 patients in the FIDELIO-DKD trial and 10 patients in the FIGARO-DKD trial). Values are presented as n (%).
FIGURE 5.
FIGURE 5.
Comparison of baseline median UACR (mg/g) and mean eGFR (mL/min/1.73 m2) of patients enrolled in recent trials investigating cardiovascular and/or renal outcomes in patients with CKD in T2D (circle sizes are proportional to the population sizes of the trials.) [12, 14, 43–49].

References

    1. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60: 850–886
    1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn.Brussels: International Diabetes Federation, 2019
    1. Abbasi M, Chertow G, Hall Y.. End-stage renal disease. Am Fam Physician 2010; 82: 1512.
    1. Luyckx VA, Tonelli M, Stanifer JW.. The global burden of kidney disease and the sustainable development goals. Bull World Health Org 2018; 96: 414–422
    1. National Health Service. Chronic Kidney Disease in England: The Human and Financial Cost. 2012. (9 November 2020, date last accessed)
    1. Wen CP, Chang CH, Tsai MK. et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017; 92: 388–396
    1. Lovre D, Shah SJ, Sihota A. et al. Managing diabetes and cardiovascular risk in chronic kidney disease patients. Endocrinol Metab Clin 2018; 47: 237–257
    1. Solomon SD, Lin J, Solomon CG. et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 2007; 116: 2687–2693
    1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR. et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339–352
    1. Pavkov ME, Collins AJ, Coresh J. et al. Kidney disease in diabetes. In: Cowie CC, Casagrande SS, Menke A. et al. (eds). Diabetes in America, 3rd edn. Publication 17-1468. Bethesda, MD, National Institutes of Health, 2018:22-1–22-80.
    1. Alicic RZ, Rooney MT, Tuttle KR.. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017; 12: 2032–2045
    1. Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150
    1. American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes. Diabetes Care 2020; 43(Suppl 1): S135–S151
    1. Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295–2306
    1. Kolkhof P, Jaisser F, Kim SY. et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol 2017; 243: 271–305
    1. Agarwal R, Kolkhof P, Bakris G. et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2020; 10.1093/eurheartj/ehaa736
    1. Whaley-Connell A, Nistala R, Chaudhary K.. The importance of early identification of chronic kidney disease. Mo Med 2011; 108: 25–28
    1. Pfizer. Aldactone (spironolactone) tablets for oral use, prescribing information. (9 November 2020, date last accessed)
    1. Upjohn UK Ltd. 2020. Eplerenone 25 mg film-coated tablets, summary of product characteristics. (09 November 2020, date last accessed)
    1. Pfizer Inc. 2020. Inspra (eplerenone) tablets for oral use, prescribing information. (09 November 2020, date last accessed).
    1. Pfizer Ltd. 2019. Aldactone 25 mg film-coated tables, summary of product characteristics. (9 November 2020, date last accessed)
    1. Pitt B, Zannad F, Remme WJ. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717
    1. Zannad F, McMurray JJ, Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21
    1. Kolkhof P, Delbeck M, Kretschmer A. et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014; 64: 69–78
    1. Lattenist L, Lechner SM, Messaoudi S. et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension 2017; 69: 870–878
    1. Barrera-Chimal J, Estrela GR, Lechner SM. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int 2018; 93: 1344–1355
    1. Kolkhof P, Barfacker L.. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017; 234: T125–T140
    1. Bakris GL, Agarwal R, Chan JC. et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015; 314: 884–894
    1. Huang LL, Nikolic-Paterson DJ, Han Y. et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol 2014; 25: 2231–2240
    1. Farquharson CA, Struthers AD.. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594–597
    1. Davies JI, Band M, Morris A. et al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004; 47: 1687–1694
    1. Yamaji M, Tsutamoto T, Kawahara C. et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J 2010; 160: 915–921
    1. Zhao JV, Xu L, Lin SL. et al. Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. J Am Soc Hypertens 2016; 10: 671–682
    1. Bayer AG. Data on file. 2015
    1. Savarese G, Carrero JJ, Pitt B. et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2018; 20: 1326–1334
    1. Amazit L, Le Billan F, Kolkhof P. et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem 2015; 290: 21876–21889
    1. Grune J, Beyhoff N, Smeir E. et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension 2018; 71: 599–608
    1. Grune J, Benz V, Brix S. et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol 2016; 67: 402–411
    1. Ma FY, Han Y, Nikolic-Paterson DJ. et al. Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628. PLoS One 2015; 10: e0145666.
    1. Filippatos G, Anker SD, Bohm M. et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37: 2105–2114
    1. Pitt B, Kober L, Ponikowski P. et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34: 2453–2463
    1. Bolignano D, Palmer SC, Navaneethan SD. et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4: CD007004
    1. Bakris GL, Agarwal R, Anker SD. et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol 2019; 50: 333–344
    1. Ruilope LM, Agarwal R, Anker SD. et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol 2019; 50: 345–356
    1. Ingelheim Boehringer . EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). (date last accessed, 21 April 2020)
    1. Fried LF, Emanuele N, Zhang JH. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892–1903
    1. Heerspink HJL, Parving HH, Andress DL. et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393: 1937–1947
    1. Heerspink HJL, Stefansson BV, Chertow GM. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020; 35: 274–282
    1. Parving HH, Brenner BM, McMurray JJ. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204–2213

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する